Model Medicines
Model Medicines is an AI-driven drug discovery company focused on developing best-in-class therapeutics for underserved diseases. They leverage their proprietary GALILEO™ platform, which integrates data science and biology, to identify and advance novel drug candidates. The company has a pipeline of 192 compounds and 67 validated assets across 12 therapeutic targets, with a focus on oncology and virology. Their approach aims to accelerate the drug development process, moving from discovery to clinical models in days rather than decades. They collaborate with leading academic and corporate labs, and their platform has been recognized in various industry publications.
Model Medicines
Model Medicines is an AI-driven drug discovery company focused on developing best-in-class therapeutics for underserved diseases. They leverage their proprietary GALILEO™ platform, which integrates data science and biology, to identify and advance novel drug candidates. The company has a pipeline of 192 compounds and 67 validated assets across 12 therapeutic targets, with a focus on oncology and virology. Their approach aims to accelerate the drug development process, moving from discovery to clinical models in days rather than decades. They collaborate with leading academic and corporate labs, and their platform has been recognized in various industry publications.
TL;DR
Founded: 2019
Headquarters: La Jolla, California
Focus: AI-driven small-molecule drug discovery (oncology, virology, inflammation)
Proprietary platform: GALILEO™ AI platform
Pipeline (reported): 192 compounds; 67 validated assets across 12 targets
Team size (reported): 13 employees
Company Overview
Problem Domain
Drug discovery and preclinical development for underserved disease areas including oncology and infectious disease.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
Recorded by third-party profiles as the most-recent listed round
Investor Signal
“Backed by multiple investors (reported count: 8), including BioTools Innovator and Nex Cubed”